Discover investment opportunities in Nano Cap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Nano Cap Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Nano Cap Stocks using our Smart AI Filter.
7 stocks found for "Nano Cap Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.78 | ±100.0% | -5.7 | 0.00% | |||
1.04 | ±100.0% | -1.2 | 0.00% | |||
0.98 | ±100.0% | — | 8.49% | |||
1.08 | ±100.0% | — | 0.00% | |||
0.74 | ±100.0% | -0.3 | 0.00% | |||
0.48 | ±92.0% | -0.2 | 0.00% | |||
0.30 | ±100.0% | -0.5 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Why might investors be interested in nano cap stocks like ATOS and SLS?
A: Investors interested in nano cap stocks such as ATOS and SLS may see potential for high growth and significant returns due to their small market capitalization. These stocks can be more volatile and often reflect early-stage or speculative businesses, offering unique opportunities despite higher risks.
Q: Are there sector-specific risks linked to nano cap stocks like CNET in the tech industry?
A: Yes, nano cap stocks in the tech industry, like CNET, often face rapid technological changes, competitive pressures, and market dependence, which can impact their performance. These stocks might experience volatile earnings and share prices due to emerging technologies and evolving consumer preferences.
Q: How do economic cycles impact nano cap stocks like BKYI?
A: Nano cap stocks like BKYI may experience heightened sensitivity to economic cycles. In economic downturns, these stocks could face liquidity issues and constrained access to capital, while upturns may present growth opportunities. Investors should assess each company's resilience to macroeconomic changes.
Q: Do nano cap stocks like TBLT offer dividend income potential?
A: Nano cap stocks like TBLT rarely offer dividend income as they often reinvest earnings to fuel growth. Investors seeking income should verify the presence or absence of dividends alongside evaluating company financial statements for signals of potential future payouts.
Q: What competitive advantages might nano cap stocks like NAOV have against larger competitors?
A: Nano cap stocks like NAOV may leverage niche markets, specialized technologies, or agile business strategies to compete with larger firms. However, these advantages carry risks due to limited resources and scalability, emphasizing the need for diligent evaluation of each company's competitive positioning.
Q: How important is liquidity for investing in nano cap stocks such as CTXR?
A: Liquidity is crucial when investing in nano cap stocks like CTXR. Low trading volumes can result in wide bid-ask spreads and potential price volatility, making it challenging to buy or sell sizable shares without impacting the stock's market price.
Biotechnology firms are increasingly turning to innovative combination therapies to tackle hard-to-treat cancers, with promising results sparking investor interest. AIM ImmunoTech Inc. AIM is the latest to capture attention, as its stock soars following a promising mid-year update from the DURIPANC Phase 2 study.
Read moreCEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups receiving surgery and radiotherapy for cancer. CEL-SCI is a player in the biotechnology sector.
Read more